Today: 13 May 2026
Celsius Stock Near 52-Week Low Before Q1 Earnings as PepsiCo Energy Bet Faces Test
6 May 2026
2 mins read

Celsius Stock Near 52-Week Low Before Q1 Earnings as PepsiCo Energy Bet Faces Test

BOCA RATON, Florida, May 6, 2026, 4:03 PM EDT

Shares of Celsius Holdings slipped on Wednesday, trading near their lowest levels in a year as the market braced for Thursday’s Q1 report. Investors are looking for any evidence that the PepsiCo deal can turn recent buyouts into steady gains. Earnings drop before the bell, with a webcast set for 8 a.m. ET.

Timing matters. Celsius isn’t only the energy drink anymore; now it manages CELSIUS, Alani Nu, and Rockstar Energy in the U.S. and Canada, all under PepsiCo’s distribution. So Thursday’s report does more than track sales trends—it gives a read on how Celsius has handled realignment in distribution and brought fresh brands into the fold over the last year.

Rothschild Redburn’s Charlie Higgs initiated coverage on Celsius with a Neutral rating this Wednesday, StreetInsider reported. The firm set a price target of $47, per Investing.com. Shares of Celsius hovered around $33, brushing against a 52-week low—well off the mark from where a number of analysts remain bullish.

Wall Street expects first-quarter revenue to reach $755.2 million, a 129.4% surge from a year ago, according to Zacks-compiled estimates. Earnings per share are forecast at 29 cents, up 61.1%. That’s a tall order, especially since CELSIUS’s gains lately have leaned on Alani Nu and Rockstar alongside its flagship label.

Celsius turned in fourth-quarter revenue of $721.6 million, surging 117% from a year ago. For all of 2025, revenue climbed 85.5% to $2.52 billion. CEO John Fieldly called 2025 “a defining year.” Still, not everything pushed higher: CELSIUS brand sales edged down in Q4, while Alani Nu set a new record and Rockstar tacked on $45 million. Celsius Holdings

Earlier, the company said it wanted Alani Nu’s integration wrapped up by the end of Q1, and Rockstar coming in Q2. That puts a spotlight on management’s commentary around shipments, shelf resets, margins. One note: when they talk about a stock-keeping unit, or SKU, they mean any individual product variant—think a particular flavor or package. Changes in SKUs can push sales between sales channels or bump numbers from one quarter to another.

PepsiCo is right in the thick of it. In August, the company put down $585 million for new Celsius preferred shares, lifting its stake to roughly 11% as converted. Around the same time, Celsius grabbed control of Rockstar Energy’s business across the U.S. and Canada. “Energy is an important growth category,” said Ram Krishnan, chief of PepsiCo Beverages U.S., back then. Business Wire

Celsius crept deeper into the Red Bull and Monster Beverage orbit after the move. Reuters reported that, with PepsiCo in its corner, Celsius and PepsiCo together grabbed about 20% of the energy-drink market last year. Keurig Dr Pepper, for its part, countered with a Ghost partnership, throwing fresh cash into the energy drink battle for share.

Short-term numbers could get messy. Investors, per Investing.com, are focused on Costco’s lower-priced Kirkland Signature energy drink, SKU reductions, tweaks to shelf placement, and higher aluminum costs. Jefferies trimmed its price target on Celsius to $67 from $71 this week—still a Buy—but warned that Alani Nu’s switch could blur this quarter’s picture.

Celsius shares lost 2.8%, settling at $32.59, leaving the company with an $8.4 billion market cap. Investors are watching Thursday’s report closely; it’s shaping up as a test of whether this recent dip is just a breather, or early evidence that momentum from the PepsiCo distribution deal remains sluggish.

Stock Market Today

  • Bicara Therapeutics Announces Inducement Grant Under Nasdaq Rule
    May 13, 2026, 9:42 AM EDT. Bicara Therapeutics has announced an inducement grant under Nasdaq listing rule 5635(c)(4), which allows companies to award stock-based compensation as an exception to shareholder approval requirements. The grant aims to attract and retain talent as the company advances its clinical-stage gene therapy pipeline. Nasdaq rule 5635(c)(4) permits such grants to encourage growth without immediate shareholder votes. Bicara's move highlights ongoing efforts by smaller biotechs to secure skilled personnel amid competitive markets.
Beyond Meat Stock Reclaims $1 Before BYND Earnings, But Nasdaq Pressure Remains
Previous Story

Beyond Meat Stock Reclaims $1 Before BYND Earnings, But Nasdaq Pressure Remains

This Is Why Loblaw Stock Fell Even as Profit Rose
Next Story

This Is Why Loblaw Stock Fell Even as Profit Rose

Go toTop